Advertisement

Mobile Banner
Mobile Banner
Mobile Banner
Loading...

Merus N.V.

MRUSNASDAQ
Healthcare
Biotechnology
$90.00
$0.00(0.00%)
U.S. Market is Open • 15:53

Merus N.V. Fundamental Analysis

Merus N.V. (MRUS) shows weak financial fundamentals with a PE ratio of -19.52, profit margin of -6.59%, and ROE of -50.79%. The company generates $0.1B in annual revenue with weak year-over-year growth of -12.38%.

Key Strengths

PEG Ratio-5.41
Current Ratio7.97

Areas of Concern

ROE-50.79%
Operating Margin-6.53%
We analyze MRUS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -533.8/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-533.8/100

We analyze MRUS's fundamental strength across five key dimensions:

Efficiency Score

Weak

MRUS struggles to generate sufficient returns from assets.

ROA > 10%
-45.19%

Valuation Score

Excellent

MRUS trades at attractive valuation levels.

PE < 25
-19.52
PEG Ratio < 2
-5.41

Growth Score

Weak

MRUS faces weak or negative growth trends.

Revenue Growth > 5%
-12.38%
EPS Growth > 10%
-11.67%

Financial Health Score

Excellent

MRUS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.02
Current Ratio > 1
7.97

Profitability Score

Weak

MRUS struggles to sustain strong margins.

ROE > 15%
-5079.22%
Net Margin ≥ 15%
-6.59%
Positive Free Cash Flow
No

Key Financial Metrics

Is MRUS Expensive or Cheap?

P/E Ratio

MRUS trades at -19.52 times earnings. This suggests potential undervaluation.

-19.52

PEG Ratio

When adjusting for growth, MRUS's PEG of -5.41 indicates potential undervaluation.

-5.41

Price to Book

The market values Merus N.V. at 10.29 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

10.29

EV/EBITDA

Enterprise value stands at -22.03 times EBITDA. This is generally considered low.

-22.03

How Well Does MRUS Make Money?

Net Profit Margin

For every $100 in sales, Merus N.V. keeps $-6.59 as profit after all expenses.

-6.59%

Operating Margin

Core operations generate -6.53 in profit for every $100 in revenue, before interest and taxes.

-6.53%

ROE

Management delivers $-50.79 in profit for every $100 of shareholder equity.

-50.79%

ROA

Merus N.V. generates $-45.19 in profit for every $100 in assets, demonstrating efficient asset deployment.

-45.19%

Following the Money - Real Cash Generation

Operating Cash Flow

Merus N.V. generates limited operating cash flow of $-317.96M, signaling weaker underlying cash strength.

$-317.96M

Free Cash Flow

Merus N.V. generates weak or negative free cash flow of $-318.57M, restricting financial flexibility.

$-318.57M

FCF Per Share

Each share generates $-4.20 in free cash annually.

$-4.20

FCF Yield

MRUS converts -4.66% of its market value into free cash.

-4.66%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-19.52

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-5.41

vs 25 benchmark

P/B Ratio

Price to book value ratio

10.29

vs 25 benchmark

P/S Ratio

Price to sales ratio

128.91

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

7.97

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.51

vs 25 benchmark

ROA

Return on assets percentage

-0.45

vs 25 benchmark

ROCE

Return on capital employed

-0.50

vs 25 benchmark

How MRUS Stacks Against Its Sector Peers

MetricMRUS ValueSector AveragePerformance
P/E Ratio-19.5229.43 Better (Cheaper)
ROE-50.79%800.00% Weak
Net Margin-658.85%-20145.00% (disorted) Weak
Debt/Equity0.020.30 Strong (Low Leverage)
Current Ratio7.974.64 Strong Liquidity
ROA-45.19%-17936.00% (disorted) Weak

MRUS outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Merus N.V.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-52.61%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-59.42%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-11.15%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ